Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of December 2025. The document serves as a transaction notification regarding insider dealings by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs). GSK plc is a global biopharma company registered in England & Wales.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to specific equity transaction notifications and does not contain financial performance data.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document details three identical transactions involving the grant of share options to senior executives.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future performance. It does not disclose risks, contingencies, or unusual items beyond the standard notification of share option grants under the Company's Share Save Plan 2022.
Important Facts for Investors to Verify
- Transaction Type: Grant of options over Ordinary Shares (ISIN: GB00BN7SWP63) pursuant to the Share Save Plan 2022.
- Transaction Date: November 28, 2025.
- Transaction Price: £14.19 per share.
- Volume: 643 options granted per individual.
- Recipients:
- James Ford (SVP and Group General Counsel, Legal and Compliance)
- David Redfern (President, Corporate Development)
- Victoria Whyte (SVP & Company Secretary)
- Exchange: London Stock Exchange (XLON).